Bioresorbable Scaffolds versus Metallic Stents in Routine PCI
- 15 June 2017
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 376 (24), 2319-2328
- https://doi.org/10.1056/nejmoa1614954
Abstract
Bioresorbable vascular scaffolds were developed to overcome the shortcomings of drug-eluting stents in percutaneous coronary intervention (PCI). We performed an investigator-initiated, randomized trial to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in the context of routine clinical practice. We randomly assigned 1845 patients undergoing PCI to receive either a bioresorbable vascular scaffold (924 patients) or a metallic stent (921 patients). The primary end point was target-vessel failure (a composite of cardiac death, target-vessel myocardial infarction, or target-vessel revascularization). The data and safety monitoring board recommended early reporting of the study results because of safety concerns. This report provides descriptive information on end-point events. The median follow-up was 707 days. Target-vessel failure occurred in 105 patients in the scaffold group and in 94 patients in the stent group (2-year cumulative event rates, 11.7% and 10.7%, respectively; hazard ratio, 1.12; 95% confidence interval [CI], 0.85 to 1.48; P=0.43); event rates were based on Kaplan–Meier estimates in time-to-event analyses. Cardiac death occurred in 18 patients in the scaffold group and in 23 patients in the stent group (2-year cumulative event rates, 2.0% and 2.7%, respectively), target-vessel myocardial infarction occurred in 48 patients in the scaffold group and in 30 patients in the stent group (2-year cumulative event rates, 5.5% and 3.2%), and target-vessel revascularization occurred in 76 patients in the scaffold group and in 65 patients in the stent group (2-year cumulative event rates, 8.7% and 7.5%). Definite or probable device thrombosis occurred in 31 patients in the scaffold group as compared with 8 patients in the stent group (2-year cumulative event rates, 3.5% vs. 0.9%; hazard ratio, 3.87; 95% CI, 1.78 to 8.42; P<0.001). In this preliminary report of a trial involving patients undergoing PCI, there was no significant difference in the rate of target-vessel failure between the patients who received a bioresorbable scaffold and the patients who received a metallic stent. The bioresorbable scaffold was associated with a higher incidence of device thrombosis than the metallic stent through 2 years of follow-up. (Funded by Abbott Vascular; AIDA ClinicalTrials.gov number, NCT01858077.)Keywords
This publication has 27 references indexed in Scilit:
- Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular ScaffoldJACC: Cardiovascular Interventions, 2016
- Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first studyEuroIntervention, 2016
- Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting StentsJournal of the American College of Cardiology, 2016
- Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery DiseaseThe New England Journal of Medicine, 2015
- Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily PracticeJACC: Cardiovascular Interventions, 2015
- Long-Term Safety of Drug-Eluting and Bare-Metal StentsJournal of the American College of Cardiology, 2015
- 2014 ESC/EACTS Guidelines on myocardial revascularizationEuropean Heart Journal, 2014
- From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?European Heart Journal, 2011
- The Pathology of Neoatherosclerosis in Human Coronary Implants: Bare-Metal and Drug-Eluting StentsJournal of the American College of Cardiology, 2011
- Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombotic RiskJournal of the American College of Cardiology, 2006